Phio Pharmaceuticals Inc
WKN: A40GMU / ISIN: US71880W5013Phio Pharmaceuticals
| eröffnet am: | 18.03.19 08:24 von: | DA_BUA |
| neuester Beitrag: | 14.01.25 10:40 von: | Highländer49 |
| Anzahl Beiträge: | 524 | |
| Leser gesamt: | 217812 | |
| davon Heute: | 93 | |
bewertet mit 3 Sternen |
||
|
|
||
18.03.19 08:24
#1
DA_BUA
Phio Pharmaceuticals
Phio Pharmaceuticals
WKN: A2N9QM
ISIN: US71880W2044
US-Symbol: PHIO
Kurs:
https://www.nasdaq.com/de/symbol/phio/real-time
WKN: A2N9QM
ISIN: US71880W2044
US-Symbol: PHIO
Kurs:
https://www.nasdaq.com/de/symbol/phio/real-time
498 Postings ausgeblendet.
23.04.23 21:58
#501
K1900
Die
Freude über die guten News hielt sich leider wirklich nicht lange. So langsam gebe ich die Hoffnung auf das hier mal ein Ausbruch nach oben gelingt der länger als nur ein paar Stunden hält… naja falls jemand ein paar Argumente dagegen hat gerne teilen. Aber das solch gute Neuigkeiten so schnell abverlangt werden bringt einen dann doch zum nachdenken.
13.07.23 23:46
#509
RichyBerlin
K1900
Irgendein 100%-Hüpfer ist hier immer drin. Man muss nur schauen, dass man dann schnell reagiert ;)
Langfristig ist schwer zu beurteilen. Die Marktkapi ist so winzig, die Projekte so teuer.
Immerhin ist wieder (winziges) Geld reingekommen
02.06.2023
https://phiopharma.com/...nt-priced-at-the-market-under-nasdaq-rules/
Langfristig ist schwer zu beurteilen. Die Marktkapi ist so winzig, die Projekte so teuer.
Immerhin ist wieder (winziges) Geld reingekommen
02.06.2023
https://phiopharma.com/...nt-priced-at-the-market-under-nasdaq-rules/
11.10.23 21:26
#511
RichyBerlin
Phio-News zu PH-894 / +50%
https://www.globenewswire.com/news-release/2023/...mpound-PH-894.html
--
s.auch #509;
"Irgendein 100%-Hüpfer ist hier immer drin. Man muss nur schauen, dass man dann schnell reagiert ;) "
--
s.auch #509;
"Irgendein 100%-Hüpfer ist hier immer drin. Man muss nur schauen, dass man dann schnell reagiert ;) "
11.10.23 22:29
#512
RichyBerlin
Phio +91%
(Der 4. ca.100%er in 1,5 Jahren)
Sehr sehr viel Volumen !
Kommt doch noch mehr?
Nachbörslich aber erstmal wieder 20% abgesackt
https://www.nasdaq.com/market-activity/stocks/phio/real-time
Sehr sehr viel Volumen !
Kommt doch noch mehr?
Nachbörslich aber erstmal wieder 20% abgesackt
https://www.nasdaq.com/market-activity/stocks/phio/real-time
06.12.23 19:10
#513
RichyBerlin
Phio
Der 5. ca.100%er in 1,5 Jahren
https://www.nasdaq.com/market-activity/stocks/phio/real-time
https://www.nasdaq.com/market-activity/stocks/phio/real-time
06.03.24 19:30
#517
RichyBerlin
Phio-News / US-Patent
+10% heute
https://finance.yahoo.com/news/...unces-patent-granted-153000859.html
https://finance.yahoo.com/news/...unces-patent-granted-153000859.html
05.07.24 22:11
#521
RichyBerlin
Phio-News
https://phiopharma.com/...share-purchase-agreement-with-triton-funds/
"Jul 5, 2024
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
Marlborough, Massachusetts–(Newsfile Corp. – July 5, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company’s common stock."
"Jul 5, 2024
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
Marlborough, Massachusetts–(Newsfile Corp. – July 5, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it has terminated its share purchase agreement with Triton Funds LP, which afforded Triton the opportunity to purchase up to 18.8% of the Company’s common stock."
16.10.24 20:53
#522
RichyBerlin
Phio +0,80€
Fehlen nur noch ca. 3,1 Mio. € Steigerung...
(Ja, wirklich)
https://www.ariva.de/aktien/...rt/chartanalyse?t=all&boerse_id=40
(Ja, wirklich)
https://www.ariva.de/aktien/...rt/chartanalyse?t=all&boerse_id=40
13.01.25 16:20
#523
RichyBerlin
Phio-News
+170%
Nicht mehr weit bis zu den 3Mio.€ ;)
https://phiopharma.com/...-from-its-ongoing-clinical-study-of-ph-762/
"Jan 13, 2025
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma
Marlborough, Massachusetts–(Newsfile Corp. – January 13, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body’s immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2 patients with a complete response or 100% tumor clearance.
Phio’s ongoing Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma.
Of the patients enrolled to date, 6 patients were diagnosed with cutaneous squamous cell carcinoma and 1 patient was diagnosed with metastatic melanoma. At Day 36 (tumor excision), while patients in the first cohort had stable disease, results are now available for the 4 patients who completed treatment in the 2nd cohort:
Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma. Partial response (90% tumor clearance) is reported for 1 patient with cutaneous squamous cell carcinoma and 1 patient had stable disease, having not progressed.
There have been no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the patients receiving intratumoral PH-762. The intratumoral injections have been well tolerated.
“We are pleased and encouraged by the profound tumor response in the second dose cohort, coupled with reassuring safety data,” said Mary Spellman MD, Phio’s acting Chief Medical Officer. “We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762.”
“These positive results in the early stages of dose escalation offer promise for our vision, ‘striving for a cancer free future’ using INTASYL technology” said Robert Bitterman, CEO of Phio Pharmaceuticals."
Nicht mehr weit bis zu den 3Mio.€ ;)
https://phiopharma.com/...-from-its-ongoing-clinical-study-of-ph-762/
"Jan 13, 2025
Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma
Marlborough, Massachusetts–(Newsfile Corp. – January 13, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body’s immune cells more effective in killing cancer cells. Phio today announced pathologic responses for patients enrolled in the 2nd cohort, which includes 2 patients with a complete response or 100% tumor clearance.
Phio’s ongoing Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumoral PH-762 in Stages 1, 2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma.
Of the patients enrolled to date, 6 patients were diagnosed with cutaneous squamous cell carcinoma and 1 patient was diagnosed with metastatic melanoma. At Day 36 (tumor excision), while patients in the first cohort had stable disease, results are now available for the 4 patients who completed treatment in the 2nd cohort:
Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma. Partial response (90% tumor clearance) is reported for 1 patient with cutaneous squamous cell carcinoma and 1 patient had stable disease, having not progressed.
There have been no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the patients receiving intratumoral PH-762. The intratumoral injections have been well tolerated.
“We are pleased and encouraged by the profound tumor response in the second dose cohort, coupled with reassuring safety data,” said Mary Spellman MD, Phio’s acting Chief Medical Officer. “We look forward to continued enrollment which will permit assessment of higher dose concentrations of PH-762.”
“These positive results in the early stages of dose escalation offer promise for our vision, ‘striving for a cancer free future’ using INTASYL technology” said Robert Bitterman, CEO of Phio Pharmaceuticals."
14.01.25 10:40
#524
Highländer49
Phio
Auch ein Winzling kann gigantische Renditen liefern: Mitten im aktuell schwierigen Umfeld für Biotech-Aktien ist am Montag die Aktie des Mini-Unternehmens Phio Pharmaceuticals um +290% auf 6,60 US$ durch die Decke geschossen. In der Spitze waren es sogar +480%. Was steckt hinter dieser Kursexplosion?
https://www.sharedeals.de/...0-altbekannte-kursrakete-zuendet-erneut/
https://www.sharedeals.de/...0-altbekannte-kursrakete-zuendet-erneut/

